Category: Drugs

What is Trulicity?|Trulicity Weight Loss Trulicity is a prescription medication used to treat type 2 diabetes. It is a brand name for the drug dulaglutide, which belongs to a class of medications called GLP-1 receptor agonists. Trulicity is administered once a week as a subcutaneous injection (injected under the skin) and works by mimicking the effects of a hormone called glucagon-like peptide-1 (GLP-1), which helps regulate blood sugar levels by increasing insulin secretion and decreasing the production of glucose by the liver. Trulicity is used in combination with diet and…

What Is Ozempic?|ozempic weight loss Ozempic is a brand name for the medication semaglutide, which is used to treat type 2 diabetes. It belongs to a class of medications called GLP-1 receptor agonists, which work by mimicking the effects of a hormone called glucagon-like peptide-1 (GLP-1) in the body. Ozempic is administered as a subcutaneous injection once a week and is used in conjunction with diet and exercise to improve blood sugar control in adults with type 2 diabetes. It helps to lower blood sugar levels by increasing insulin secretion,…

Basics about Diclofenac sodium topical gel Life doesn’t stop for arthritis pain. Arthritis Pain Relieving Gel, with diclofenac sodium 1%, a non-steroidal anti-inflammatory drug (NSAID) is clinically proven to relieve arthritis pain. Diclofenac sodium topical gel 1% is a  topical arthritis pain reliever, this medicated gel penetrates skin at the application site to deliver significant relief within 7 days with 4 times-per-day use. You can apply this gel to hand, wrist, elbow, foot, ankle or knee for daily treatment of arthritis pain. Arthritis Pain Relieving Gel, Diclofenac Sodium 1%, reduces…

Basics of Mounjaro (Tirzepatide) Mounjaro, also known as Tirzepatide, is a novel treatment for Type 2 diabetes that has been generating a lot of buzz in the pharmaceutical industry. Mounjaro is similar to others medications and has both useful effects and possible side effects.  Mounjaro has potential side effects that patients should be aware of before starting treatment. Some of the most common side effects include nausea, vomiting, and diarrhea. These symptoms can be especially bothersome during the first few weeks of treatment, but they usually improve over time. We…

Description of Ibutilide (Corvert) Ibutilide, a substituted methane sulfonamide derivative, is an intravenous Class III antiarrhythmic agent indicated for rapid conversion of atrial fibrillation or atrial flutter to normal sinus rhythm. Prior to approval of ibutilide, electrical cardioversion was the recommended choice for rapid conversion of atrial fibrillation or flutter to normal sinus rhythm. No other approved pharmacologic agent is indicated for rapid conversion of atrial arrhythmias. Ibutilide began the FDA approval process in October 1994 and was finally approved December 28, 1995. Application to market the drug in Sweden…

Description of Micafungin (Mycamine) Micafungin is an intravenous echinocandin antifungal agent, with antifungal activity against Candida albicans, C. glabrata, C. guilliermondii, C. krusei, C. parapsilosis, and C. tropicalis. Micafungin, a semisynthetic lipopeptide, is derived from a fermentation product of Coleophoma empetri. It is approved for use in adults and pediatric patients 4 months and older to treat esophageal candidiasis, candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses, and for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. The drug is also approved for use in pediatric patients younger than 4 months of age to treat candidemia,…

Description of Pancuronium (PAVULON) Pancuronium is a parenteral, long-acting, nondepolarizing, neuromuscular blocking agent indicated as an adjunct to general anesthesia to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Pancuronium is approximately one-third less potent than vecuronium, with a longer duration of action at initially equipotent doses. Pancuronium has little effect on histamine release at usual doses and is not likely to cause clinically significant bronchospasm compared to agents with histamine-releasing properties such as atracurium and succinylcholine; however, pancuronium may cause significant tachycardia and…

Description of Meprobamate Meprobamate is an oral carbamate derivative used as an anxiolytic. It is similar in structure to carisoprodol; in fact, meprobamate is an active metabolite of carisoprodol. Meprobamate is indicated for the treatment of anxiety disorders or for the short-term symptomatic treatment of anxiety in adults and children 6 years and older; however, historically the drug has also been used for its sedative properties. Due to the availability of other therapies, meprobamate is not considered a treatment of choice for anxiety disorders in adults or pediatric patients. Clinical…

Description of Decitabine Decitabine is a pyrimidine antimetabolite. It is indicated for the treatment of adult patients with myelodysplastic syndrome. Severe myelosuppression has been reported with decitabine therapy; monitor complete blood counts during therapy. Mechanism of Action of Decitabine Decitabine is an antimetabolite that can replace cytosine in DNA but, unlike cytosine, it cannot be methylated. The exact mechanism of decitabine activity has not been determined and may involve multiple pathways. Decitabine is thought to primarily act by correcting DNA methylation, a major mechanism for gene expression. In some cancer…

Description of Sargramostim (Leukine) Sargramostim is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). It works by promoting proliferation and differentiation of hematopoietic progenitor cells. Sargramostim is used as primary prophylaxis following induction therapy in older patients with acute myelogenous leukemia; for peripheral blood stem cell (PBSC) mobilization for collection by leukapheresis; following an autologous bone marrow transplantation (BMT) in patients with non-Hodgkin’s lymphoma, acute lymphoblastic leukemia, and Hodgkin’s disease; following an allogeneic BMT from an HLA-matched related donor; and following engraftment failure or delay after an autologous or allogeneic BMT.…